Delving into the Latest Updates on PMI-03 with Synapse

Overview

Basic Info

Drug Type

Contrast agent, Small molecule drug

Synonyms

Target-

Mechanism

Magnetic resonance imaging enhancers

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Alzheimer DiseaseNeuroinflammationParkinson Disease+ [1]

Inactive Indication

Inflammation

Originator Organization

Precision Molecular Inc.

Active Organization

D&D Pharmatech Co., Ltd.Startup

Precision Molecular Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDOcular tension decreases with increasing postmortem interval (PMI) and eyes collapse with extreme progression of postmortem change; however, time-related changes in postmortem computed tomography (PMCT) findings have not been clarified. This study aimed to quantitatively evaluate the vitreous volume and CT values of the vitreous body to clarify time-related changes in PMCT.METHODSWe retrospectively reviewed PMCT images of the eyes of subjects who underwent autopsy at our institution between July 2023 and February 2024. They were classified into four PMI groups: PMI-1: < 1 day, PMI-2: 1-2 days, PMI-3: 3-6 days, PMI-4: ≥ 7 days. The vitreous volumes and mean CT values of the vitreous chambers were measured. Additionally, the presence of intraocular gas and crystalline lens dislocation was observed.RESULTSThe PMCT images of 131 eyes of 66 patients (41 males, 25 females) were analyzed. The mean age was 63.7 (22-99) years. The volume of the vitreous cavity was significantly decreased at PMI-3 and PMI-4, which indicated scleral depression. Intraocular gas appeared in PMI-4. Lens dislocation began at PMI-3 and was more frequently observed at PMI-4 and in the higher-temperature environment group.CONCLUSIONOcular findings on PMCT are useful for estimating the time of death.

100 Deals associated with PMI-03

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 1	KR	D&D Pharmatech Co., Ltd.Startup	30 Jan 2022
Neuroinflammation	Phase 1	KR	D&D Pharmatech Co., Ltd.Startup	30 Jan 2022
Parkinson Disease	Phase 1	KR	D&D Pharmatech Co., Ltd.Startup	30 Jan 2022
Nerve Degeneration	Phase 1	-	Precision Molecular Inc.	-
Neurodegenerative Diseases	Discovery	US	Precision Molecular Inc.	22 Aug 2019
Inflammation	Discovery	US	Precision Molecular Inc.	28 Jul 2019